Barclays Maintains Overweight on Cytokinetics, Raises Price Target to $40
Barclays analyst Carter Gould maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $28 to $40.
Cytokinetics Announces Proposed $200M Public Offering of Common Stock
Cytokinetics, Incorporated (NASDAQ:CYTK) today announced plans to offer, subject to market and other conditions, $200,000,000 of shares of its common stock in an underwritten public offering. There can be no assurance as
Mid-Afternoon Market Update: Dow Tumbles 850 Points; Aehr Test Systems Shares Surge
Toward the end of trading Monday, the Dow traded down 2.46% to 33,835 while the NASDAQ fell 1.24% to 14,248.21. The S&P also fell, dropping 1.93% to 4,243.58.
Analysts See Higher Success Chances For Cytokinetics’ Heart Disease Candidate After Positive Phase 2 Data
Today, Cytokinetics Incorporated (NASDAQ: CYTK) reported positive REDWOOD-HCM Phase 2 data showing CK-274 treatment for ten weeks
HC Wainwright & Co. Maintains Buy on Cytokinetics, Raises Price Target to $53
HC Wainwright & Co. analyst Joseph Pantginis maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $41 to $53.
Mid-Day Market Update: Crude Oil Dips 6%; Cytokinetics Shares Spike Higher
Midway through trading Monday, the Dow traded down 2.28% to 33,896.40 while the NASDAQ fell 1.31% to 14,238.93. The S&P also fell, dropping 1.74% to 4,251.79.
30 Stocks Moving In Monday’s Mid-Day Session
Gainers
Cytokinetics, Incorporated (NASDAQ: CYTK) jumped 56.4% to $30.07 after the company disclosed topline results from Cohorts 1 and 2 of REDWOOD-HCM.
Needham Maintains Buy on Cytokinetics, Raises Price Target to $48
Needham analyst Chad Messer maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $33 to $48.